Acurian Announces Its Contribution of Over 600 Randomized Patients in Global, Phase III Diabetes Trial at Therapeutic Conference in Amsterdam

Amsterdam, The Netherlands - Acurian, Inc., a leading, fullservice provider of patient recruitment and retention solutions, announced today at the Patient Recruitment & Retention for Diabetes & Obesity Studies Conference in Amsterdam that it recently completed its enrollment contribution of over 600 diabetes patients for a global, nine-protocol diabetes study.

According to Roger Smith, Acurian's Senior Vice President of Operations, the program started in 2010 and is the company's largest diabetes project to date. Acurian's patient contribution represented over 30% of the total enrollment goal, and was additive to the number of patients sourced by the participating research sites' own practices. Through its patient contribution, Acurian reduced the enrollment timeline by 11 weeks on average across the nine protocols. For one protocol, the sponsor realized a seven-month time savings had it relied only on site-based enrollment.

"We have a very rich history with regard to supporting diabetes clinical studies," stated Smith. "This program, however, truly showcases our ability to provide significant, additive patient enrollments to accelerate trial timelines. This is particularly noteworthy in diabetes, a therapeutic area with increasingly nuanced protocols and fierce competition for clinical trial participants."

Smith stated that Acurian generated over 20,000 pre-qualified referrals through direct mail to regional subsets of its database of over eight million diabetes patients, along with advertising within traditional online and social networks deployed internationally. Acurian's patient database houses over half of the diagnosed type 2 diabetics in the United States.

"Finding and enrolling qualified diabetes patients will continue to be a challenge for sponsors and sites, despite the growing incidence and prevalence of the disease," indicated Smith. "This is particularly true in the United States, but we are well positioned to help sponsors recruit, enroll and retain diabetes patients in all corners of the globe."

About Acurian
Acurian is a leading full-service provider of clinical trial patient recruitment and retention solutions for the life sciences industry. Through its proprietary patient panel of over 65 million patients, centralized advertising capabilities, and a fully hosted enrollment management technology platform, Acurian is able to identify, contact, prescreen, and refer patients into clinical trials, all while supporting investigator sites with services to maximize the randomization potential of every referred patient. Since 1998, Acurian has supported over 400 protocols for more than 60 companies. Acurian's investors include Euclid SR Partners, ProQuest Investments, JP Morgan Partners, Flatiron Partners, CDP Capital Technology Ventures, and Merck Capital Ventures.

SOURCE: Acurian